A health economic model to assess the long term effects and cost-effectiveness of PEG IFN α-2a in hepatitis C virus infected patients

Acta Gastro-Enterologica Belgica

Volumn 67, Issue 1, 2004, Pages 1-8

  Annemans, Lieven ^a,b,d   Warie, H ^a   Nechelput, M ^c   Peraux, B ^c  

^a HEDM   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c Roche Pharmaceuticals   (Belgium)

^d NONE   (Belgium)

Author keywords

Cost effectiveness; Hepatitis C virus; Interferons

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; GENOTYPE; HEALTH ECONOMICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MODEL; MORBIDITY; MORTALITY; QUALITY ADJUSTED LIFE YEAR;

ANTIVIRAL AGENTS; BELGIUM; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MODELS, ECONOMIC; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 2142695339     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. DEVROEY D., VAN CASTEREN V., VRANCKX R. Clinical acute viral hepatitis encountered by belgian general practitioners. Int. J. Infect. Dis., 1997, 2: 105-109.
2. BEUTELS M., VAN DAMME P., AELVOET W. Prevalence of hepatitis A,B and C in the flemish population. Eur J. Epidemiol., 1997, 13: 275-280.
3. SHEPHERD J., WAUGH N., HEWITSON P. Combination therapy (interferon α and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol. Assess, 2000, 4 (33): 1-67.
4. DELWAIDE J. Economic evaluation of chronic hepatitis C treatment by interferon-ribavirin combination therapy in Belgium. Acta Gastroenterol. Belg., 2002 Oct-Dec, 65 (4): 233-236.
5. DE HEMPTINNE B., on behalf of the Belgian Liver Transplantation Activity in Adults patients in Belgium. Acta Gastroenterol. Belg., 2001, 64: D04.
6. BERNSTEIN D., KLEINMAN L., BARKER C.M. et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology, 2002, 35: 704-708.
7. FOSTER G.R. Hepatitis C virus infection: quality of life and side effects of treatment. J. Hepatol., 1999, 31 (suppl. 1): 250-254.
8. ZEUZEM S. What is (cost) effective in patients with chronic hepatitis C virus infectionα Eur. J. Gastroenterol. Hepatol., 2001, 13: 473-476.
9. ZEUZEM S., FEINMAN S.V., RASENACK J. et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med., 2000, 343: 1666-1672.
10. HEATHCOTE E.J., SCHIFFMAN M.L., COOKSLEY G.E. et al. Peg-interferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med., 2000, 343: 1673-1680.
11. ZEUZEM S., HEATHCOTE J., MARTIN N. et al. Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Expert Opin. Investig. Drugs, 2001, 10: 2201-2213.
12. REDDY K.R., WRIGHT T.L., POCKROS P.J. et al. Efficacy and safety of Pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C. Hepatology, 2001, 33: 433-438.
13. FRIED M., SHIFFMAN M., REDDY K. et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C infection. N. Engl. J. Med., 2002, 347: 975-982
14. HADZIYANNIS S., CHEINQUER H., MORGAN T. et al. Peginterferon alfa-2a in combination with ribavirin: efficacy and safety results from a phase 3, randomized, double-blind, multicentre study examining effect of duration of treatment and ribavirin dose. J. Hepatol., 2002, 36 (suppl. 1): A1.
15. SONNENBERG F.A., BECK J.R. Markov models in medical decision making: a practical guide. Med Dec Making, 1993, 13: 322-331.
16. YOUNOSSI Z.M., SINGER M.E., MC HUTCHISON J.G. et al. Cost-effectiveness of interferon a2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology, 1999, 30: 1318-1324.
17. WONG J.B., POYNARD T., LING M.H. et al. Cost-effectiveness of 24 or 48 weeks of interferon a-2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am J Gastroenterol, 2000, 95: 1524-1530.
18. SAGMEISTER M., WONG J.B., MULLHAUPT B. et al. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol, 2001, 13: 483-488.
19. SENNFÄLT K., REICHARD O., HULTKRANTZ R. et al. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol, 2001, 36 (8): 870-876.
20. WONG J.B., MCQUILLAN G.M., MCHUTCHISON J.G. et al.: Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health, 2000, 90: 1562-1569.
21. BENNETT W.G., INOUE Y., BECK J.R. et al. Estimates of the cost-effectiveness of a single course of interferon-alpha2b in patients with histologically mild chronic hepatitis C. Ann. Intern. Med., 1997, 127: 855-865.
22. KIM W.R., POTERUCHA J.J., HERMANS J.E. et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann. Intern. Med., 1997, 127: 866-874.
23. WONG J.B., NEVENS F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b as initial treatment of chronic hepatitis in Belgium (extended abstract). Acta gastroenterol. Belg., 2002, 65: 1-2.
24. SIMOONS M.L. Cholesterol-lowering therapy, a recommendation from the Health Council. Ned. Tijdschr. Geneeskd., 2000 Dec 16, 144 (51): 2442-2444.